Khandoker Usran Ferdous

Researcher

University of Arkansas for Medical Sciences

faculty

4 h-index 19 pubs 57 cited

Research Areas

Cancer Immunotherapy and Biomarkers Viral Infections and Vectors Pancreatic and Hepatic Oncology Research Immune Response and Inflammation Cancer Treatment and Pharmacology Genomics and Phylogenetic Studies Molecular Biology Techniques and Applications Monoclonal and Polyclonal Antibodies Research

Links

Lab Website

Is this your profile? Verify and claim your profile

OverviewAI-generated summary

Khandoker Usran Ferdous investigates the potential of oncolytic viruses and repurposed vaccines as cancer immunotherapies. His research has explored the use of the live attenuated trivalent MMR vaccine for cancer immunotherapy and the development of engineered oncolytic viruses to combat cancer. Ferdous' work includes enhancing immune responses in hepatocellular carcinoma (HCC) using novel oncolytic Jurona virus in conjunction with immune checkpoint blockade. He also studies strategies to improve the effectiveness of neoadjuvant virotherapy in pancreatic cancer by targeting the tumor stroma, aiming to improve resectability. His recent publications examine resistance signatures to oncolytic vesiculoviruses in pancreatic ductal adenocarcinoma and the immunomodulatory effects of systemic delivery of synthetic vesiculoviruses. Ferdous collaborates with researchers Mulu Z. Tesfay, Martin J. Cannon, Alexei G. Basnakian, and Steven R. Post, with whom he shares multiple publications.

Metrics

h-index: 4
Publications: 19
Citations: 57

Selected Publications

Multimodal reprogramming of the tumor microenvironment by MMR and dual checkpoint blockade in hepatocellular carcinoma models (2025) DOI
Abstract B022: Reprogramming Apoptotic Resistance in PDAC Through Synthetic Oncolytic Immunotherapy (2025) DOI
Viral warfare: unleashing engineered oncolytic viruses to outsmart cancer’s defenses (2025) DOI
Repeat Systemic Delivery of Cross-Neutralization Resistant Synthetic Vesiculoviruses Immunomodulates the Tumor Microenvironment (2025) DOI
Abstract 950: Engineered oncolytic vesiculovirus downsizes pancreatic tumor and boosts immune response (2025) DOI
Abstract 2155: Phage display discovery of Trop-2 peptide for targeted liposomal chemo-immunotherapy in lung cancer (2025) DOI
Abstract 945: Live attenuated MMR vaccines modulate tumor immune cell infiltration and synergize with standard of care to prolong survival in preclinical HCC models (2025) DOI
Abstract 947: Engineering a synthetic oncolytic virus to overcome apoptotic resistance and induce immunogenic cell death in pancreatic ductal adenocarcinoma (2025) DOI
Resistance signatures to oncolytic vesiculoviruses in pancreatic ductal adenocarcinoma (2025) DOI
Enhancing immune response and survival in hepatocellular carcinoma with novel oncolytic Jurona virus and immune checkpoint blockade (2024) DOI
Enhancing Neoadjuvant Virotherapy’s Effectiveness by Targeting Stroma to Improve Resectability in Pancreatic Cancer (2024) DOI
Abstract 588: Preclinical evaluation of novel chimeric vesiculovirus mediated expression of proteolytic enzymes targeting two major stromal components of pancreatic ductal adenocarcinoma (2024) DOI
Abstract 5004: Oncolytic Jurona-driven systemic and intratumoral immunotherapy combined with immune checkpoint blockade boost immune response and survival in hepatocellular carcinoma models (2024) DOI
Repurposing live attenuated trivalent MMR vaccine as cost-effective cancer immunotherapy (2022) DOI